Patents Assigned to Pronova Biopharma Norge AS
-
Patent number: 11612579Abstract: A preconcentrate comprising a fatty acid oil mixture that contains EPA and DHA, preferably in the form of ethyl ester or triglyceride, and at least one surfactant. The preconcentrates are capable of forming a self-nanoemulsifying drug delivery system, a self-microemulsifying drug delivery system or a self-emulsifying drug delivery system (SNEDDS, SMEDDS or SEDDS) in an aqueous solution. The application is also directed to a food supplement preconcentrate.Type: GrantFiled: March 9, 2010Date of Patent: March 28, 2023Assignee: PRONOVA BIOPHARMA NORGE ASInventors: Svein Olaf Hustvedt, Preben Houlberg Olesen, Gunnar Berge, Jo Erik Johnsrud Klaveness
-
Compositions comprising a fatty aged oil mixture and a free fatty acid, and methods and uses thereof
Patent number: 11523999Abstract: Compositions comprising a fatty acid oil mixture and at least one free fatty acid, and uses thereof are disclosed. Further disclosed are preconcentrates capable of forming a self-nanoemulsifying drug delivery system (SNEDDS), a self-microemulsifying drug delivery system (SMEDDS) or self-emulsifying drug delivery systems (SEDDS) in an aqueous solution. Preferred fatty acids are eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in a form chosen from ethyl ester and triglyceride.Type: GrantFiled: March 24, 2020Date of Patent: December 13, 2022Assignee: PRONOVA BIOPHARMA NORGE ASInventors: Svein Olaf Hustvedt, Preben Houlberg Olesen, Gunnar Berge, Anette Mullertz -
Patent number: 11395811Abstract: Preconcentrates comprising a fatty acid oil mixture and at least one surfactant, and methods and uses thereof are disclosed. The preconcentrates are capable of forming a self-nanoemulsifying drug delivery system (SNEDDS), a self-microemulsifying drug delivery system (SMEDDS), or self-emulsifying drug delivery systems (SEDDS) in an aqueous solution.Type: GrantFiled: March 9, 2010Date of Patent: July 26, 2022Assignee: ProNova BioPharma Norge ASInventors: Svein Olaf Hustvedt, Preben Houlberg Olesen, Gunnar Berge, Jo Erik Johnsrud Klaveness
-
Compositions comprising a fatty acid oil mixture and a free fatty acid, and methods and uses thereof
Patent number: 10028928Abstract: Compositions comprising a fatty acid oil mixture and at least one free fatty acid, and uses thereof are disclosed. Further disclosed are preconcentrates capable of forming a self-nanoemulsifying drug delivery system (SNEDDS), a self-microemulsifying drug delivery system (SMEDDS) or self-emulsifying drug delivery systems (SEDDS) in an aqueous solution. Preferred fatty acids are eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in a form chosen from ethyl ester and triglyceride.Type: GrantFiled: November 14, 2016Date of Patent: July 24, 2018Assignee: Pronova Biopharma Norge ASInventors: Svein Olaf Hustvedt, Preben Houlberg Olesen, Gunnar Berge, Anette Mullertz -
Patent number: 9585896Abstract: The present disclosure relates to pharmaceutical compositions comprising omega-3 fatty acids and vitamin D for use in at least one of preventing and treating psoriasis, and to food supplement, dietary supplement, nutritional supplement, over-the-counter (OTC) supplement, medical food, or pharmaceutical grade supplement compositions comprising omega-3 fatty acids and vitamin D for use in improving at least one parameter associated with psoriasis.Type: GrantFiled: March 15, 2013Date of Patent: March 7, 2017Assignee: PRONOVA BIOPHARMA NORGE ASInventors: David A Fraser, Alexis Garras
-
Compositions comprising a fatty acid oil mixture and a free fatty acid, and methods and uses thereof
Patent number: 9532963Abstract: Compositions comprising a fatty acid oil mixture and at least one free fatty acid, and uses thereof are disclosed. Further disclosed are preconcentrates capable of forming a self-nanoemulsifying drug delivery system (SNEDDS), a self-microemulsifying drug delivery system (SMEDDS) or self-emulsifying drug delivery systems (SEDDS) in an aqueous solution. Preferred fatty acids are eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in a form chosen from ethyl ester and triglyceride.Type: GrantFiled: March 9, 2010Date of Patent: January 3, 2017Assignee: Pronova Biopharma Norge ASInventors: Svein Olaf Hustvedt, Preben Houlberg Olesen, Gunnar Berge, Anette Müllertz -
Publication number: 20160374975Abstract: A composition and method of treating patients diagnosed with NAFLD is disclosed. The composition contains n-3 polyunsaturated fatty acids (PUFAs) for treatment of NAFLD patients, wherein the amount of PCB 153 in the composition has been minimized. The composition is administered to a patient in a sufficient amount and for a sufficient time to increase the level of n-3 PUFAs or to correct a deficiency of n-3 PUFAs in the patient's blood. The method increases the level of n-3 PUFAs without contributing to the body burden of PCB 153.Type: ApplicationFiled: June 22, 2016Publication date: December 29, 2016Applicant: Pronova BioPharma Norge ASInventor: Carola Rosseland
-
Patent number: 9447360Abstract: The present invention refers to a process for reducing the amount of undesired components in an oil composition, particularly in an oil composition comprising omega-3 polyunsaturated fatty acids. The process of the present invention provides efficient removal of undesired water-soluble (hydrophilic) components and undesired fat-soluble (lipophilic) components from an oil composition in order to obtain a purified concentrate, e.g. a highly purified concentrate enriched in omega-3 polyunsaturated fatty acids.Type: GrantFiled: October 31, 2013Date of Patent: September 20, 2016Assignee: Pronova Biopharma Norge ASInventors: Sverre Sondbø, Olav Thorstad
-
Patent number: 9394228Abstract: Methods are disclosed to treat or prevent at least one disease or condition in a subject in need thereof comprising administering a compound of Formula (I): or a pharmaceutically acceptable salt, or ester thereof, wherein R1 and R2 are independently chosen from a hydrogen atom or linear, branched, and/or cyclic C1-C6 alkyl groups, with the proviso that R1 and R2 are not both hydrogen or a pharmaceutically acceptable salt or ester thereof. Such diseases or conditions may relate to coronary heart disease (CHD), for example atherosclerosis; metabolic syndrome/insulin resistance; and/or a dyslipidemic condition such as hypertriglyceridemia (HTG), elevated LDL-cholesterol, elevated total-cholesterol, elevated Apo B and low HDL-cholesterol. The present disclosure further provides for a method of reducing atherosclerosis development. Pharmaceutical compositions comprising a compound of Formula (I) are also disclosed.Type: GrantFiled: November 3, 2011Date of Patent: July 19, 2016Assignee: PRONOVA BIOPHARMA NORGE ASInventors: Ragnar Hovland, Tore Skjæret, David Fraser
-
Patent number: 9370493Abstract: Compositions comprising a fatty acid oil mixture and at least one free fatty acid in a coated capsule or a coated tablet form suitable for oral administration, and methods of use thereof, are disclosed. Further disclosed are preconcentrates comprising a fatty acid oil mixture, at least one surfactant, and optionally at least one free fatty acid, in a coated capsule or a coated tablet form, and methods of use thereof. The preconcentrates are capable of forming a self-nanoemulsifying drug delivery system (SNEDDS), a self-microemulsifying drug delivery system (SMEDDS), or self-emulsifying drug delivery systems (SEDDS) in an aqueous solution.Type: GrantFiled: October 22, 2010Date of Patent: June 21, 2016Assignee: Pronova Biopharma Norge ASInventors: Jo Erik Johnsrud Klaveness, Gunnar Berge, Svein Olaf Hustvedt, Preben Houlberg Olesen, Anette Müllertz
-
Patent number: 9365482Abstract: Methods for the efficient synthesis of fatty acid derivatives and their intermediates are provided.Type: GrantFiled: February 27, 2014Date of Patent: June 14, 2016Assignee: Pronova Biopharma Norge ASInventors: Tore Skjæret, Ragnar Hovland
-
Patent number: 9282760Abstract: A method is disclosed for treatment and prevention of obesity, an overweight condition or for controlling body weight reduction, wherein an effective amount of a fatty acid composition comprising at least one of (all-Z omega-3)-5,8,11,14,17-eicosapentaenoic acid (EPA) and (all-Z omega-3)-4,7,10,13,16,19-docosahexaenoic acid (DHA) or any combinations thereof, is administered to a human or an animal. Additionally, a dietary product is disclosed, containing a fatty acid composition comprising at least one of EPA and DHA or any combinations thereof, for non-medical treatment of obesity, an overweight condition and/or for supporting and controlling body weight reduction. Finally, a method is disclosed for supplementing a dietary product with a fatty acid composition mentioned above.Type: GrantFiled: December 17, 2004Date of Patent: March 15, 2016Assignee: PRONOVA BIOPHARMA NORGE ASInventors: Morten Bryhn, Jan Kopecky
-
Publication number: 20160009625Abstract: Methods for the efficient synthesis of fatty acid derivatives and their intermediates are provided.Type: ApplicationFiled: February 27, 2014Publication date: January 14, 2016Applicant: PRONOVA BIOPHARMA NORGE ASInventors: Tore SKJÆRET, Ragnar HOVLAND
-
Publication number: 20150079164Abstract: The present disclosure relates to food supplement, dietary supplement, nutritional supplement, over-the-counter (OTC) supplement, medical food, or pharmaceutical grade supplement compositions comprising omega-3 fatty acids and vitamin D for use in improving at least one parameter associated with acne and/or eczema (dermatitis).Type: ApplicationFiled: March 15, 2013Publication date: March 19, 2015Applicant: Pronova Biopharma Norge ASInventors: David A. Fraser, Alexis Garras
-
Publication number: 20150056276Abstract: The present disclosure relates to pharmaceutical compositions comprising omega-3 fatty acids and vitamin D for use in at least one of preventing and treating psoriasis, and to food supplement, dietary supplement, nutritional supplement, over-the-counter (OTC) supplement, medical food, or pharmaceutical grade supplement compositions comprising omega-3 fatty acids and vitamin D for use in improving at least one parameter associated with psoriasis.Type: ApplicationFiled: March 15, 2013Publication date: February 26, 2015Applicant: Pronova Biopharma Norge ASInventors: David A. Fraser, Alexis Garras
-
Publication number: 20140316002Abstract: The present disclosure relates to lipid compounds of general formula (I) wherein R1 is chosen from a C10-C22 alkyl group, a C10-C22 alkenyl group having 1-6 double bonds, and a C10-C22 alkynyl group having 1-6 triple bonds; R2 and R3 are the same or different and may be selected from different substituents; Y is chosen from sulphur, sulfoxide, and sulfone; and X is a carboxylic acid or a derivative thereof, a carboxylic ester, a carboxylic anhydride, or a carboxamide; or a pharmaceutically acceptable salt, complex, or solvate thereof. The present disclosure also relates to pharmaceutical compositions and lipid compositions comprising such compounds, and methods of using such compounds such as for treating diseases related to cardiovascular, metabolic, and/or inflammatory diseases.Type: ApplicationFiled: April 28, 2014Publication date: October 23, 2014Applicant: PRONOVA BIOPHARMA NORGE ASInventors: Anne Kristin Holmeide, Ragnar HOVLAND, Morten BRÆNDVANG
-
Patent number: 8829215Abstract: The present invention relates to a process for preparing compositions of high concentrations of omega-3 fatty acids from krill. Furthermore, the invention relates to a composition comprising high concentrations of omega-3 fatty acids, and a lipid fraction from krill comprising high amounts of fatty acids with chain length C14 and C16.Type: GrantFiled: May 15, 2009Date of Patent: September 9, 2014Assignee: Pronova Biopharma Norge ASInventors: Harald Breivik, Olav Thorstad
-
Publication number: 20140221439Abstract: The present disclosure relates to lipid compounds of the general formula (I): R1—O—C(R2)(R3)—X??(I) wherein R1 is a C10-C22 alkyl group, a C10-C22 alkenyl group having 1-6 double bonds, or a C10-C22 alkynyl group having 1-6 triple bonds; R2 and R3 are the same or different and may be chosen from different substituents; and X is a carboxylic acid or a derivative thereof, such as a carboxylic ester, a carboxylic anhydride, a phospholipid, triglyceride, or a carboxamide; or a pharmaceutically acceptable salt, solvate, solvate of such salt, or a prodrug thereof. The present disclosure also relates to pharmaceutical compositions and lipid compositions comprising at least one compound according to the present disclosure, and to such compounds for use as medicaments or for use in therapy, in particular for the treatment of diseases related to the cardiovascular, metabolic, and inflammatory disease area.Type: ApplicationFiled: April 11, 2014Publication date: August 7, 2014Applicant: PRONOVA BIOPHARMA NORGE ASInventors: Ragnar Hovland, Anne Kristin HOLMEIDE, Tore SKJÆRET, Morten BRÆNDVANG
-
Patent number: 8759558Abstract: The present invention relates to lipid compounds of the general formula (I): wherein R1 is selected from a C10-C22 alkyl, a C10-C22 alkenyl having 1-6 double bonds, and a C10-C22alkynyl having 1-6 triple bonds; R2 and R3 are the same or different and may be selected from a group of different substituents; Y is selected from sulphur, sulfoxide, and sulfone; and X represents a carboxylic acid or a derivative thereof, a carboxylic ester, a carboxylic anhydride or a carboxamide; or a pharmaceutically acceptable salt, complex or solvate thereof. The invention also relates to pharmaceutical compositions and lipid compositions comprising such compounds, and to such compounds for use as medicaments or for use in therapy, in particular for the treatment of diseases related to the cardiovascular, metabolic and inflammatory disease area.Type: GrantFiled: July 13, 2009Date of Patent: June 24, 2014Assignee: Pronova Biopharma Norge ASInventors: Anne Kristin Holmeide, Ragnar Hovland, Morten Brændvang
-
Patent number: D854933Type: GrantFiled: February 17, 2017Date of Patent: July 30, 2019Assignee: PRONOVA BIOPHARMA NORGE ASInventors: James Whittaker, Thor Morten Wangen, Øyvind Ihle